Citations

Showing 10 of 108081 citations.

Copeptin levels in hospitalized infants and children with suspected vasopressin-dependent disorders: a case series
Nofal, Alaa Al , Hanna, Christian , Lteif, Aida, Pittock, Siobhán T. , Schwartz, Jonathan , Creo, Ana L. , Lteif, Aida N, Schwartz, Jonathan D. , Creo, Ana , Al Nofal, Alaa , Hanna, Christian , Brumbaugh, Jane E.

Mayo Clinic

Journal of Pediatric Endocrinology and Metabolism | April 8, 2023 | Volume: 36 | Issue: 5 | Pages: 492-499

10.1515/jpem-2022-0525 | PMID 37029788 Get It

Abstract Objectives There have been recent advances assessing copeptin levels in adults with suspected disorders of vasopressin release. Very limited data exits on copeptin levels in children and infants, especially in a critically-ill hospitalized population where hyper- and hypo-natremia are very common. Our objective is to describe the institutional experience assessing copeptin levels in hospitalized infants and children with hyper- or hypo-natremia. Methods We performed a single-center retrospective case series of all infants, children, and adolescents who had an ultrasensitive plasma copeptin level obtained between 2019-2021. Results A total of 29 critically ill patients (6 infants) were identified with 38 % of patients having copeptin levels after neurosurgical procedures for tumors or trauma. Approximately 13/17 children with hypernatremia had central diabetes insipidus (central diabetes insipidus) to diagnose CDI, A copeptin level ≤ 4.9 pmol/L resulted in an 88 % sensitivity (95 % CI 47–99 %), and 66 % specificity (95 % CI 30–93 %). Amongst those with hyponatremia levels were more variable, 8/12 children had syndrome of inappropriate antidiuresis (SIAD) with copeptin levels ranging 4.7–72.6 pmol/L. Conclusions While difficult to conclude due to multiple limitations, this case series highlights that typical copeptin cutoffs used to diagnose DI in adults in an ambulatory setting may also translate to a critically-ill pediatric population. Large prospective studies are needed to confirm this observation. In addition, postoperative copeptin levels could potentially be utilized as an additional marker to predict permanent from transient DI, but much larger studies are needed. Further work is needed to establish normative copeptin levels in infants and patients with SIAD.
Clinical Images: Tongue ulceration in giant cell arteritis associated with asymptomatic retinal ischemia
Guarda, Max , Ghaffar, Umar , Koster, Matthew J. , Koster, Matthew J , Warrington, Kenneth J.

Mayo Clinic

ACR Open Rheumatology | April 8, 2023 | Volume: 5 | Issue: 7 | Pages: 331-331

10.1002/acr2.11544 | PMID 37029506 Get It

Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
Tran, Benjamin V. , Moris, Dimitrios , Markovic, Daniela , Zaribafzadeh, Hamed , Lai, Quirino , Florman, Sander , Tabrizian, Parissa , Haydel, Brandy , Ruiz, Richard M., Klintmalm, Göran B. , Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Lerut, Jan , Nguyen, Mindie H. , Viveiros, André , Schaefer, Benedikt , Hoppe‐Lotichius, Maria , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, R. Mark , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Busuttil, Ronald W. , Barbas, Andrew S. , Lai, Quirino , Florman, Sander S , Tabrizian, Parissa , Haydel, Brandy , Klintmalm, Goran , Lee, David D , Taner, Burcin , Hoteit, Maarouf , Levine, Matthew H , Cillo, Umberto , Verna, Elizabeth C , Halazun, Karim J , Tevar, Amit D , Humar, Abhinav , Chapman, William C , Vachharajani, Neeta , Ciccarelli, Olga , Nguyen, Mindie H , Melcher, Marc L , Viveiros, Andre , Schaefer, Benedikt , Hoppe-Lotichius, Maria , Mittler, Jens , Markmann, James F , Rossi, Massimo , Mobley, Constance , Ghobrial, Mark , Schnickel, Gabriel T , Sudan, Debra L , Hong, Johnny C , Rana, Abbas , Jones, Christopher M , Busuttil, Ronald W , Barbas, Andrew S , Agopian, Vatche G , Moris, Dimitrios , Henao, Ricardo , Ruiz, Richard , Taner, C. Burcin , Vitale, Alessandro , Melcher, Marc L. , Carney, Carol A., Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | April 7, 2023 | Volume: 29 | Issue: 7 | Pages: 683-697

10.1097/lvt.0000000000000145 | PMID 37029083 Get It

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
Clinical metrics and tools for provider assessment and tracking of trigonocephaly
Chern, Joshua J. , Ahn, Edward S. , Chamis, Megan, Paro, Mitch R., Lambert, William A. , Stoltz, Petronella, Hersh, David S. , Martin, Jonathan E. , Leclair, Nathan K. , Bookland, Markus J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 7, 2023 | Volume: 32 | Issue: 1 | Pages: 82-90

10.3171/2023.2.peds22511 | PMID 37029682 Get It

OBJECTIVE Quantitative measurements of trigonocephaly can be used to characterize and track this phenotype, which is associated with metopic craniosynostosis. Traditionally, trigonocephaly metrics were extracted from CT scans; however, this method exposes patients to ionizing radiation. Three-dimensional optical scans are another option but are not routinely available in most outpatient settings. Recently, the authors developed semiautomated artificial intelligence algorithms that extract craniometric data from orthogonal 2D photographs. Although 2D photographs are safe, inexpensive, and straightforward to obtain, the accuracy of photograph-based craniometrics in comparison to CT and 3D optical scan correlates has not been established. In this study the authors compared the classification power of 2D photograph–based metrics of trigonocephaly with four CT-based metrics and one 3D optical scan–based metric in a heterogeneous series of patients who presented to an outpatient craniofacial clinic. METHODS In this study the authors performed retrospective craniometric analyses of patient 2D photographs, 3D optical scans, and CT scans. Imaging-derived craniometrics include the 2D photograph–based anterior arc angle (AAA2D-photo), anterior-posterior ratio (APR2D-photo), and anterior-middle ratio (AMR2D-photo); the CT-based anterior arc angle (AAACT), metopic index (MICT), endocranial-bifrontal angle (eBFACT), and interfrontal angle (IFACT); and the 3D optical scan–based anterior arc angle (AAA3D-optical). Receiver operating characteristics (ROCs) were used to identify craniometrics strongly descriptive of trigonocephaly. Interrater comparisons were made between paired trigonocephaly measurements obtained from photographs and either CT scans or 3D optical scans. RESULTS There were 13 photograph-based and CT-based pairs and 22 paired measurements from 2D photographs and 3D optical scans. AAA displayed the strongest classification capacity across all three imaging modalities. Significant agreement was observed between AAACT and AAA2D-photo (intraclass correlation coefficient [ICC] = 0.68 [95% CI 0.24–0.89], p = 0.0035), and AAA3D-optical and AAA2D-photo (ICC = 0.70 [95% CI 0.41–0.87], p < 0.0001). There was no significant correlation between APR2D-photo or AMR2D-photo and conventional CT-based metrics describing longitudinal width ratios (MICT). CONCLUSIONS Photograph-based craniometrics are powerful tools that can be used to quantify the severity of trigonocephaly and exhibit high concordance with standard measurements derived from CT scans and 3D optical scans. The authors developed and freely share a research-use application to calculate trigonocephaly metrics from 2D photographs. Given the availability of digital photography, lack of ionizing radiation, and low cost of photograph-based craniometric derivation, this technique may be useful to supplement routine ambulatory care and objectively track outcomes following treatment.
Graph convolutional network-based fusion model to predict risk of hospital acquired infections
Tariq, Amara , Lancaster, Lin, Elugunti, Praneetha, Siebeneck, Eric, Banerjee, Imon , Patel, Bhavik N. , Moriarty, James, Banerjee, Imon , Siebeneck, Eric, Noe, Katherine H. , Borah, Bijan J. , Moriarty, James P.

Mayo Clinic

Journal of the American Medical Informatics Association | April 7, 2023 | Volume: 30 | Issue: 6 | Pages: 1056-1067

10.1093/jamia/ocad045 | PMID 37027831 Get It

Abstract Objective Hospital acquired infections (HAIs) are one of the top 10 leading causes of death within the United States. While current standard of HAI risk prediction utilizes only a narrow set of predefined clinical variables, we propose a graph convolutional neural network (GNN)-based model which incorporates a wide variety of clinical features. Materials and Methods Our GNN-based model defines patients’ similarity based on comprehensive clinical history and demographics and predicts all types of HAI rather than focusing on a single subtype. An HAI model was trained on 38 327 unique hospitalizations while a distinct model for surgical site infection (SSI) prediction was trained on 18 609 hospitalization. Both models were tested internally and externally on a geographically disparate site with varying infection rates. Results The proposed approach outperformed all baselines (single-modality models and length-of-stay [LoS]) with achieved area under the receiver operating characteristics of 0.86 [0.84–0.88] and 0.79 [0.75–0.83] (HAI), and 0.79 [0.75–0.83] and 0.76 [0.71–0.76] (SSI) for internal and external testing. Cost-effective analysis shows that the GNN modeling dominated the standard LoS model strategy on the basis of lower mean costs ($1651 vs $1915). Discussion The proposed HAI risk prediction model can estimate individualized risk of infection for patient by taking into account not only the patient’s clinical features, but also clinical features of similar patients as indicated by edges of the patients’ graph. Conclusions The proposed model could allow prevention or earlier detection of HAI, which in turn could decrease hospital LoS and associated mortality, and ultimately reduce the healthcare cost.
Hemostatic In Vitro Properties of Novel Plasma Supernatants Produced from Late-storage Low-titer Type O Whole Blood
Mihalko, Emily , Rahn, Katelin, Seheult, Jansen N. , Cap, Andrew P., Triulzi, Darrell J., Yazer, Mark H. , Shea, Susan M. , Mihalko, Emily P , Shea, Susan M , Seheult, Jansen N , Srinivasan, Amudan J. , Spinella, Philip C. , Cap, Andrew P., Neal, Matthew D

Mayo Clinic

Anesthesiology | April 7, 2023 | Volume: 139 | Issue: 1 | Pages: 77-90

10.1097/aln.0000000000004574 | PMID 37027803 Get It

Background The use of low-titer group O whole blood is increasing. To reduce wastage, unused units can be converted to packed red blood cells. Supernatant is currently discarded post-conversion; however, it could be a valuable transfusable product. The aim of this study was to evaluate supernatant prepared from late-storage low-titer group O whole blood being converted to red blood cells, hypothesizing it will have higher hemostatic activity compared to fresh never-frozen liquid plasma. Methods Low-titer group O whole blood supernatant (n = 12) prepared on storage day 15 was tested on days 15, 21, and 26 and liquid plasma (n = 12) on 3, 15, 21, and 26. Same-day assays included cell counts, rotational thromboelastometry, and thrombin generation. Centrifuged plasma from units was banked for microparticle characterization, conventional coagulation, clot structure, hemoglobin, and additional thrombin generation assays. Results Low-titer group O whole blood supernatant contained more residual platelets and microparticles compared to liquid plasma. At day 15, low-titer group O whole blood supernatant elicited a faster intrinsic clotting time compared to liquid plasma (257 ± 41 vs . 299 ± 36 s, P = 0.044), and increased clot firmness (49 ± 9 vs . 28 ± 5 mm, P < 0.0001). Low-titer group O whole blood supernatant showed more significant thrombin generation compared to liquid plasma (day 15 endogenous thrombin potential 1,071 ± 315 vs . 285 ± 221 nM·min, P < 0.0001). Flow cytometry demonstrated low-titer group O whole blood supernatant contained significantly more phosphatidylserine and CD41 + microparticles. However, thrombin generation in isolated plasma suggested residual platelets in low-titer group O whole blood supernatant were a greater contributor than microparticles. Additionally, low-titer group O whole blood supernatant and liquid plasma showed no difference in clot structure, despite higher CD61 + microparticle presence. Conclusions Plasma supernatant produced from late-storage low-titer group O whole blood shows comparable, if not enhanced, in vitro hemostatic efficacy to liquid plasma. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Major, Ajay , Yu, Jovian , Shukla, Navika , Karrison, Theodore , Treitman, Rachel, Haverkos, Bradley M. , Godfrey, James , Babcook, Melissa A., Voorhees, Timothy , Carlson, Sophie G. , Gaut, Daria , Oliai, Caspian , Winter, Allison , Hill, Brian T. , Bansal, Radhika , Nizamuddin, Imran , Fitzgerald, Lindsey , Stephens, Deborah M. , Hu, Marie , Bachanová, Veronika , Slade, Michael , Singh, Nathan , Bishop, Michael R. , Riedell, Peter A. , Haverkos, Bradley M , Voorhees, Timothy J , Romancik, Jason T , Bansal, Radhika , Villasboas, Jose Caetano , Karmali, Reem , Stephens, Deborah M , Pophali, Priyanka , Trabolsi, Asaad , Schatz, Jonathan H , Hu, Marie , Slade, Michael J , Singh, Nathan , Ahmed, Nausheen , McGuirk, Joseph , Riedell, Peter A , Bachanova, Veronika , Major, Ajay , Che, Yan, Kamdar, Manali , Oliai, Caspian H , Romancik, Jason T. , Villasboas, José C. , Karmali, Reem , Pophali, Priyanka A. , Ahmed, Nausheen , McGuirk, Joseph P. , Bishop, Michael Russell , Kline, Justin Paul

Mayo Clinic

Blood Advances | April 7, 2023 | Volume: 7 | Issue: 16 | Pages: 4528-4538

10.1182/bloodadvances.2023010016 | PMID 37026796 Get It

AbstractCheckpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (&gt;180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post–CAR-T outcomes.
Multiple abnormal peripheral blood gene expression assay results are correlated with subsequent graft loss after kidney transplantation
Heilman, Raymond L. , Mai, Martin, Smith, Byron H. , Park, Walter D. , Holman, John , Stegall, Mark D. , Smith, Byron , Park, Walter , Holman, John , Stegall, Mark D , Fleming, James N

Mayo Clinic

Clinical Transplantation | April 7, 2023 | Volume: 37 | Issue: 8 | Pages: No page available

10.1111/ctr.14987 | PMID 37026820 Get It

AbstractBackgroundThe aim of this study was to correlate peripheral blood gene expression profile (GEP) results during the first post‐transplant year with outcomes after kidney transplantation.MethodsWe conducted a prospective, multicenter observational study of obtaining peripheral blood at five timepoints during the first post‐transplant year to perform a GEP assay. The cohort was stratified based on the pattern of the peripheral blood GEP results: Tx‐all GEP results normal, 1 Not‐TX had one GEP result abnormal and >1 Not‐TX two or more abnormal GEP results. We correlated the GEP results with outcomes after transplantation.ResultsWe enrolled 240 kidney transplant recipients. The cohort was stratified into the three groups: TX n = 117 (47%), 1 Not‐TX n = 59 (25%) and >1 Not‐TX n = 64 (27%). Compared to the TX group, the >1 Not‐TX group had lower eGFR (p < .001) and more chronic changes on 1‐year surveillance biopsy (p = .007). Death censored graft survival showed inferior graft survival in the >1 Not‐TX group (p < .001) but not in the 1 Not‐TX group. All graft losses in the >1 Not‐TX group occurred after 1‐year post‐transplant.ConclusionsWe conclude that a pattern of persistently Not‐TX GEP assay correlates with inferior graft survival.
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
Tyson, Mark D. , Palou, Juan, Rodríguez, Óscar , Mir, Maria Carmen , Dickstein, Rian J., Guerrero‐Ramos, Félix , Scarpato, Kristen R., Messing, Edward M. , Cutie, Christopher J., Maffeo, John, Raybold, Bradley, Chau, Albert, Stromberg, Katharine A., Keegan, Kirk A., Morris, David S. , Palou, Joan, Hafron, Jason M. , Chau, Albert, Stromberg, Katharine

Mayo Clinic

Journal of Urology | April 7, 2023 | Volume: 209 | Issue: 5 | Pages: 890-900

10.1097/ju.0000000000003195 | PMID 37026631 Get It